ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO1012

Polymorphisms in the Exon 1 of the MBL2 Gene Are Not Associated with a Poor Prognosis in Membranous Nephropathy

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Coêlho, Maria Carolina Romeiro Figueiroa Benicio, Hospital das Clínicas HC - UFPE, Recife, Brazil
  • Oliveira, Camila Barbosa lyra, Hospital das Clínicas HC - UFPE, Recife, Brazil
  • Vasconcelos, Carolina Andrade jordão, IMIP, Recife, Brazil
  • Costa, Denise Maria do Nascimento, Hospital das Clínicas HC - UFPE, Recife, Brazil
  • Vajgel, Gisele, Hospital das Clínicas HC - UFPE, Recife, Brazil
  • Cavalcante, Maria Alina G.M., Hospital das Clínicas HC - UFPE, Recife, Brazil
  • Valente, Lucila Maria, Hospital das Clínicas HC - UFPE, Recife, Brazil
Background

MBL2 polymorphisms may be associated with the activation of lectin pathway by IgG4 subclass antibodies in membranous nephropathy (MN). Studies involving systemic lupus erythematosus (SLE) have conflicting results, with some data sugesting the association between MBL2 polymorphisms with more severe forms of disease. We investigated whether the prognosis among patients with MN differ according to the presence or absence of these polymorphisms.

Methods

Polymorphisms in the exon 1 of the MBL2 gene (codons 52, 54 and 57) were evaluated in 59 patients with the two main etiologies of MN in our setting: idiopathic (35 patients) and secondary to SLE (24 patients). We divided the patients into two groups according to the presence or absence of the polymorphisms and analyzed proteinuria as a response parameter after 6 months, 1 and 5 years.

Results

The 59 patients were analysed as their baseline clinical characteristics (Table 1). In both genders, as in both MN etiologies, the presence of polymorphism was predominant. There was no distinction between groups with and without polymorphism with respect to age, initial LDL, serum creatinine (SCr), proteinuria, serum Albumin (SAlb) and blood pressure. After 6 months, 1 year and 5 years, there was no difference in relation to SCr and SAlb among the groups evaluated. No differences in mean and median levels of proteinuria were observed when we compared the patientes with and without MBL2 polymorphisms after 6 months (4.1 x 3.8, p = 0.838), 1 year (2.1 x 1.7, p = 0.876) and 5 years (0.2 x 1.0, p = 0.110),.

Conclusion

Our data did not support the hypothesis that MBL2 polymorphisms may be associated with a poor prognosis in patients with MN. Because of the small number of subjects studied, a larger study of MN patients would seem necessary to confirm these findings.